US 11104737
ACVR2A-specific antibody and method of treatment of muscle atrophy
granted A61KA61K39/3955A61K47/542
Quick answer
US patent 11104737 (ACVR2A-specific antibody and method of treatment of muscle atrophy) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K39/3955, A61K47/542, A61K47/543, A61K47/60